G0S2 Inhibitors
G0S2 Inhibitors refer to a class of chemicals that can directly or indirectly influence the function or expression of the G0/G1 switch gene 2 (G0S2) protein. This protein plays crucial roles in various cellular processes, including cell cycle control, apoptosis, and lipid metabolism. These inhibitors operate primarily by affecting various signaling pathways that ultimately regulate the expression or function of G0S2. Many G0S2 inhibitors, such as Ly294002, Wortmannin, and PP2, target the PI3K/Akt pathway, which is a major regulator of G0S2. By inhibiting PI3K, these chemicals suppress Akt activation, leading to a decrease in G0S2 expression. Rapamycin, an inhibitor of mTORC1, operates in a similar way, suppressing the activation ofS6K1, a downstream target of mTORC1, which negatively regulates G0S2 expression. PD98059 and U0126, both inhibitors of MEK, reduce the activation of ERK1/2, which has been implicated in the upregulation of G0S2, thereby leading to a decrease in G0S2 expression.
Yet other inhibitors, such as SB203580, BAY 11-7082, and PDTC, target different pathways. SB203580 inhibits p38 MAPK, resulting in decreased G0S2 expression, as G0S2 is a downstream target of the p38 MAPK pathway. BAY 11-7082 and PDTC, both inhibitors of NF-κB, decrease G0S2 expression, given that G0S2 is also a downstream target of the NF-κB pathway. SP600125, an inhibitor of JNK, reduces the activation of c-Jun, which in turn regulates G0S2. Finally, ZM 336372 and KN-93 inhibit RAF-1 kinase and CaMKII respectively, suppressing the activation of downstream pathways that regulate G0S2. In conclusion, the central theme among these diverse chemicals is their ability to modulate various signaling pathways that control the expression or function of G0S2, placing them in the class of G0S2 inhibitors. These chemicals demonstrate the complex interplay of cellular signaling in the regulation of key proteins, such as G0S2, and provide a unique insight into how cellular processes can be modulated.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Ly294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks). G0S2 is a downstream target of the PI3K/Akt pathway, so when Ly294002 inhibits PI3K, it also suppresses the activation of Akt, leading to a decrease in G0S2 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1). When Rapamycin inhibits mTORC1, it also suppresses the activation of S6K1, a downstream target of mTORC1, which can negatively regulate G0S2 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK1. By inhibiting MEK1, PD98059 can reduce the activation of ERK1/2, which has been implicated in the upregulation of G0S2. Thus, the inhibition of MEK1 by PD98059 can lead to a decrease in G0S2 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK. Inhibition of p38 MAPK by SB203580 can decrease the expression of G0S2, as G0S2 is a downstream target of the p38 MAPK pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another potent inhibitor of PI3K. Similar to Ly294002, Wortmannin can suppress the activation of Akt, which leads to a decrease in G0S2 expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK. When SP600125 inhibits JNK, it can reduce the activation of c-Jun, which is a transcription factor known to upregulate G0S2. Therefore, the inhibition of JNK by SP600125 can lead to a decrease in G0S2 expression. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 is an inhibitor of NF-κB. Inhibition of NF-κB by BAY 11-7082 can decrease the expression of G0S2, as G0S2 is a downstream target of the NF-κB pathway. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $46.00 | 2 | |
ZM 336372 is an inhibitor of RAF-1 kinase, which is upstream of MEK in the MAPK pathway. By inhibiting RAF-1 kinase, ZM 336372 can suppress the activation of MEK and ERK, leading to a decrease in G0S2 expression. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family kinases. When PP2 inhibits Src, it can reduce the activation of the PI3K/Akt pathway, leading to a decrease in G0S2 expression. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
KN-93 is an inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII). When KN-93 inhibits CaMKII, it can reduce the activation of the AMPK pathway, which can regulate G0S2 expression. | ||||||